Inhibikase Therapeutics Inc
IKT
Closed
$2.39
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Key stats
Open
$2.38
Volume
538.24K
Market cap
$327.91M
Prev. close
$2.35
Impl / hst vl
-
Open interest
$0.00
$2.37
Day’s Range
$2.41
$1.49
52W Range
$2.53
Valuation
5
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
2.01
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-
FCF growth
3.18
Analysts estimates
Consensus rating
Buy
The average rating from top 7 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.12
The top 10 analysts forecasts that 12-month price may increase by 156.07%, with a low of $3.03 and a high of $8.40
$3.03
Low
$6.12
Avg
$8.40
High
Current price
Earnings
Q4 ‘25 revenue
$0.00
Q4 ‘25 net income
-$12.73M
Revenue
Net income
Previous EPS
-$0.10
Estimate EPS
-$0.11
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply